Aqueous oral care fluoride treatment compositions and methods

Abstract

To provide compositions that are simply applied to teeth as varnishes and work in a short time like gel / foam formulations, and methods for treatment.SOLUTION: An aqueous oral care fluoride treatment composition is disclosed, wherein the composition includes: 0.1 wt.% to 3.0 wt.% of a crosslinked poly acid having carboxylic acid side groups; a pharmaceutically acceptable buffer; 1.0 wt.% to 2.5 wt.% of sodium fluoride; 0.025 wt.% to 1.75 wt.% of a multivalent cation salt; and at least 60 wt.% water; wherein the weight percentages are based on the total weight of the aqueous composition. Also disclosed are a method of providing fluoride to a patient's tooth surface, and a method of reducing the incidence of dental caries.SELECTED DRAWING: None

Description

[Background technology]

[0001] Fluoride treatment involves applying fluoride to the tooth surface to form fluorapatite and calcium fluoride.

[0002] Currently, two primary in-office fluoride treatment methods are in use. One treatment method uses a fluoride gel / foam in a tray. This method requires several grams of fluoride gel to be stored in a tray and then placed on the teeth in the patient's mouth. The tray is left in the mouth for 1 to 4 minutes, with the gel / foam in contact with the teeth. The gel / foam formulation is an aqueous system containing 2% sodium fluoride. This material requires the use of suction to draw excess gel from the mouth to avoid ingesting unnecessary large amounts of fluoride.

[0003] Another treatment method is dental fluoride varnish. Most fluoride varnishes on the market are rosin / ethanol-based formulations with hydrophobic properties. The varnish is applied to the teeth and left in place for several hours to allow the fluoride to be released from the composition. Dentists typically use fluoride varnish for in-office fluoride treatments. Most dental fluoride varnishes contain 5% sodium fluoride. The dose of the varnish is approximately 0.5 g. Dental varnishes place much less fluoride in the patient's mouth than fluoride gels / foams. Therefore, fluoride intake is lower with fluoride varnish. Furthermore, although fluoride varnishes are easier to apply because they are simply painted onto the patient's teeth, fluoride varnish treatments are more labor-intensive than gel treatments, and fluoride varnish treatments leave patients with an unpleasant "stained teeth" sensation.

[0004] A composition that is easy to apply to teeth as a varnish and has a short duration of action similar to a gel / foam formulation is desired. Summary of the Invention

[0005] The present disclosure provides aqueous oral care fluoride treatment compositions and methods of treatment (eg, methods of applying fluoride to a patient's tooth surfaces).

[0006] Such compositions can be used as in-office fluoride treatment compositions. They can be formulated into compositions that can be painted onto tooth surfaces, if desired. They can provide fluoride efficacy similar to that of varnishes, but in a shorter period of time than gel / foam formulations.

[0007] In one embodiment, the present disclosure provides an aqueous oral care fluoride treatment composition comprising: 0.1% to 3.0% by weight of a crosslinked polyacid having pendant carboxylic acid groups; a pharmaceutically acceptable buffer; 1.0% to 2.5% by weight of sodium fluoride; 0.025% to 1.75% by weight of a polyvalent cation salt; and at least 60% by weight of water, wherein the weight percentages are based on the total weight of the aqueous composition.

[0008] In another embodiment, the present disclosure provides a method of providing fluoride to a patient's dental surfaces, the method involving applying an aqueous oral care fluoride treatment composition disclosed herein to the patient's dental surfaces.

[0009] In another embodiment, the present disclosure provides a method for reducing the incidence of dental caries, the method involving applying an aqueous oral care fluoride treatment composition disclosed herein to a patient's dental surfaces.

[0010] As used herein, the term "alkyl" refers to a monovalent group that is a radical of an alkane, and includes linear (i.e., straight-chain), branched, cyclic, and bicyclic alkyl groups, and combinations thereof, including both unsubstituted and substituted alkyl groups. Unless otherwise specified, alkyl groups typically contain 1 to 100 carbon atoms. In some embodiments, alkyl groups contain 1 to 60 carbon atoms, 1 to 30 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 3 carbon atoms. Examples of "alkyl groups" include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, t-butyl, isopropyl, n-octyl, n-heptyl, ethylhexyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, and the like.

[0011] The terms "polymer" and "polymeric material" include, but are not limited to, organic homopolymers, copolymers, such as block copolymers, graft copolymers, random copolymers, and copolymers, terpolymers, etc., as well as blends and modifications thereof. Furthermore, unless otherwise specifically limited, the term "polymer" is intended to encompass all possible geometric configurations of the material. These configurations include, but are not limited to, isotactic, syndiotactic, and atactic symmetries.

[0012] The terms "comprise" and variations thereof do not have a limiting meaning where these terms appear in the specification and claims. Such terms are understood to imply the inclusion of a recited step or element, or group of steps or elements, but not the exclusion of any other step or element, or group of steps or elements. "Consisting of" means including and limiting to whatever follows the phrase "consisting of." Thus, the phrase "consisting of" indicates that the recited elements are necessary or mandatory, and that no other elements may be present. "Consisting essentially of" means including any elements listed after the phrase, and is limited to other elements that do not interfere with or contribute to the action or function specified in this disclosure for those recited elements. Thus, the phrase "consisting essentially of" indicates that the recited elements are necessary or mandatory, but that other elements are optionally included and may or may not be present depending on whether they materially affect the action or function of the recited elements.

[0013] The words "preferred" and "preferably" refer to embodiments of the present disclosure that may provide certain benefits, under certain circumstances, although other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present disclosure.

[0014] In this application, terms such as "a," "an," and "the" are not intended to refer only to a singular entity, but are intended to include the general class of which a specific example may be used for illustration. The terms "a," "an," and "the" are used interchangeably with the phrases "at least one" and "one or more." The phrases "at least one of" and "including at least one of," following a list, refer to any one of the items in the list and any combination of two or more items in the list.

[0015] The term "or" is generally used in its ordinary sense, including "and / or," unless the context clearly dictates otherwise.

[0016] The term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements.

[0017] Further, all numbers herein are deemed to be modified by the term "about," and in certain embodiments, preferably, by the term "exactly." When used herein with respect to a measured quantity, the term "about" refers to the variation in the measured quantity that may be expected by one of ordinary skill in the art, exercising a degree of care commensurate with the measurement, the purpose of the measurement, and the precision of the measuring device used. As used herein, "up to" (e.g., up to 50) before a number includes that number (e.g., 50).

[0018] Further herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range, and the endpoints thereof (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0019] The term "room temperature" refers to a temperature between 20°C and 25°C, or between 22°C and 25°C.

[0020] References throughout this specification to "one embodiment," "an embodiment," "particular embodiments," or "some embodiments" mean that a particular feature, structure, composition, or characteristic described in connection with an embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of such phrases in various places throughout this specification are not necessarily all referring to the same embodiment of the present disclosure. Furthermore, particular features, structures, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.

[0021] The above summary of the present disclosure is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The following description more particularly exemplifies exemplary embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited lists serve only as a representative group and should not be interpreted as an exclusive list. DETAILED DESCRIPTION OF THE INVENTION

[0022] The present disclosure provides aqueous oral care fluoride treatment compositions. The present disclosure also provides methods for delivering fluoride to a patient's tooth surfaces, as well as methods for reducing the incidence of dental caries. Such methods involve applying the aqueous oral care fluoride treatment compositions described herein to a patient's tooth surfaces.

[0023] In certain embodiments, applying the aqueous oral care fluoride treatment composition comprises painting the treatment composition onto the patient's tooth surfaces.

[0024] In certain embodiments, applying the aqueous oral care fluoride treatment composition comprises dispensing the treatment composition into a dental tray and attaching the tray with the treatment composition therein to the patient's tooth surfaces. In certain embodiments, the dental tray comprises an orthodontic aligner treatment tray.

[0025] The aqueous oral care fluoride treatment compositions of the present disclosure comprise at least 60%, at least 70%, or at least 80% by weight of water, based on the total weight of the aqueous composition. In certain embodiments, the treatment compositions comprise up to 96%, or up to 90% by weight of water, based on the total weight of the aqueous composition.

[0026] The treatment compositions of the present disclosure are aqueous compositions. While they may contain small amounts of organic solvents (e.g., a (C1-C4) alcohol such as ethanol), preferably they do not contain organic solvents that function as a liquid carrier (as opposed to organic solvents used as carriers / solvents for flavorings or sweeteners). For example, certain additives may be provided as a solution or dispersion in an organic solvent as a liquid carrier. If any organic solvent (that functions as a liquid carrier) is present in the aqueous oral care fluoride treatment compositions of the present disclosure, it is present in an amount of less than 5% by weight, based on the total weight of the aqueous composition.

[0027] The aqueous oral care fluoride treatment compositions of the present disclosure include a pharmaceutically acceptable buffering agent. The type and amount of such buffering agent are selected to provide the treatment composition with a pH of at least 6, or at least 6.5. In certain embodiments, the type and amount of such buffering agent are selected to provide the treatment composition with a pH of at most 8, at most 7.5, or at most 7. In certain embodiments, particularly in methods for reducing the incidence of dental caries, the type and amount of such buffering agent are selected to provide the treatment composition with a pH of 6.5 to 7.5, or a pH of 7.0, in accordance with the Federal Register, Vol. 39, No. 94, May 14, 1974 monograph entitled "Topical Fluoride Preparations for Reducing Incidence of Dental Caries."

[0028] Polyacid The aqueous oral care fluoride treatment compositions of the present disclosure include a cross-linked polyacid, which can be a homopolymer or copolymer of one or more monomers having one or more carboxylic acid groups.

[0029] Examples of monomers having one or more carboxylic acid groups include acrylic acid, maleic acid, maleic anhydride, itaconic acid, vinyl ethers, alkyl acrylates, and sugars. Various combinations of such materials may be used if desired. In certain embodiments, the crosslinked polyacids include homopolymers or copolymers of acrylic acid, maleic acid, itaconic acid, (C10-C30) alkyl acrylates, and combinations thereof. In certain embodiments, the crosslinked polyacids include crosslinked polyacrylic acid homopolymers.

[0030] Examples of cross-linking agents include allyl sucrose, allyl pentaerythritol, glycerol, diglycerol, polyglycerol, polyalkenyl alcohol, or divinyl glycol. Various combinations of cross-linking agents may be used if desired. In certain embodiments, polyacrylic acid is cross-linked with allyl sucrose or allyl pentaerythritol.

[0031] Suitable polyacids of the present disclosure help provide compositions that can be used to develop semi-solid and liquid formulations with a wide range of flow and rheological properties. Polyacids can also provide one or more of the following: highly efficient thickening agents, suspending agents, stabilizers that eliminate settling problems, flow control agents, and bioadhesives, even when used at low concentrations (e.g., 0.1% to 3.0% by weight). Preferred polyacids swell when hydrated and neutralized, forming colloidal dispersions. Insoluble components in the suspension are then trapped in the interstitial spaces between the hydrogel particles, thereby forming a stable dispersion.

[0032] The polyacids can have a variety of viscosities. In certain embodiments, the crosslinked polyacid has a viscosity of 4,000 to 100,000 centipoise (cP) in a pH 7.5 buffer at 0.5% by weight.

[0033] Exemplary polyacids include linear polyacrylic acid, acrylic acid copolymers, maleic acid / maleic anhydride copolymers, itaconic acid copolymers, vinyl ether and maleic anhydride copolymers, such as those available under the trade name GANTREZ (Ashland), high molecular weight cross-linked polyacrylic acid homopolymers and copolymers, such as those available under the trade name CARBOPOL (Lubrizol Life Sciences), and carboxylic acid modified cellulose (CMC), such as those available under the trade name KLUCEL (Ashland). These homopolymers and copolymers have the same type of carboxylic acid side groups that can be neutralized with several alkaline chemicals to form aqueous buffer systems. These polymers are water-soluble or dispersible, or can form hydrogels in aqueous solutions.

[0034] A preferred polyacid is a high-molecular-weight polymer of acrylic acid chemically crosslinked with polyalkenyl alcohol or divinyl glycol and available under the trade name CARBOPOL. Each primary particle can be seen as a network of polymer chains interconnected by crosslinks, resulting in polymers with molecular weights of up to 300-400 million daltons. Without crosslinks, the primary particles are a collection of linear polymer chains, physically entangled but not chemically bonded. These polymers swell up to 1,000 times their original volume in water (10 times their original diameter) and form gels when exposed to pH environments above a pKa of 6±0.5. Carboxylate groups on the polymer backbone provide negative interparticle repulsion, which contributes to the swelling of the polymer. The gel contains a large number of swollen microgel particles and interstitial spaces in which insoluble particles can be trapped (suspended).

[0035] CARBOPOL polymer microgels are easily displaced by shear, but the macrogel structure quickly reforms when shear is stopped. This allows highly viscous suspensions to be easily stirred or pumped, with instantaneous recovery immediately upon cessation of stirring or pumping. CARBOPOL polymers swell when hydrated and neutralized, forming colloidal dispersions and trapping insoluble components.

[0036] Suitable CARBOPOL polymers include those available as CARBOPOL 974P NF, CARBOPOL 971P NF, and CARBOPOL 71G NF polymers. Of these, CARBOPOL 974P NF polymer is particularly preferred. It is highly crosslinked and produces a highly viscous gel similar to mayonnaise. The viscosity of CARBOPOL 974P NF polymer at pH 7 is 10,000 mPa at a 0.2% concentration, as measured by Brookfield viscosity at 20 revolutions per minute (rpm). * s, 30,000 mPa at 0.5% concentration * s, 60,000 mPa at 1.0% concentration * s, 85,000 mPa at 2.0% concentration * The viscosity of CARBOPOL 974P NF polymer at pH 6 and pH 7 is very similar.

[0037] Another suitable cross-linked polyacid is available from Lubrizol Advanced Materials under the trade name NOVEON AA-1 polycarbophil (a high molecular weight acrylic acid polymer cross-linked with divinyl glycol).

[0038] The compositions of the present disclosure comprise at least 0.1 wt. %, or at least 0.5 wt. %, of a crosslinked polyacid having pendant carboxylic acid groups, based on the total weight of the aqueous composition. The compositions of the present disclosure comprise at most 3.0 wt. %, or at most 1.5 wt. %, of a crosslinked polyacid having pendant carboxylic acid groups, based on the total weight of the aqueous composition.

[0039] Multivalent cation salts Suitable polyvalent cation salts for use in the compositions of the present disclosure include +2 polyvalent cations, +3 polyvalent cations, or combinations thereof. In certain embodiments, the polyvalent cation salt comprises a +3 polyvalent cation. Various combinations of such salts may be used if desired.

[0040] Examples of suitable multivalent cations in the salt include those selected from Ca, Mg, Ba, Mn, Fe, Zn, Al, Cu, and combinations thereof. In certain embodiments, the multivalent cations are selected from Ca, Zn, Al, and combinations thereof. In certain embodiments, the multivalent cations include Al and Ca.

[0041] Examples of suitable counterions in the polyvalent cation salts include those selected from chloride, nitrate, gluconate, lactate, acetate, and sulfate. Various combinations of counterions may be used if desired. Furthermore, the salts may also include their hydrates.

[0042] In certain embodiments, the calcium-containing polyvalent cation salt (i.e., calcium salt) is selected from calcium chloride, calcium nitrate, calcium gluconate, calcium lactate gluconate, calcium acetate, hydrates thereof, and combinations thereof. In certain embodiments, the calcium-containing polyvalent cation salt is selected from calcium chloride, calcium nitrate, hydrates thereof, and combinations thereof.

[0043] In certain embodiments, the aluminum-containing polyvalent cation salt (i.e., aluminum salt) is selected from aluminum chloride, aluminum sulfate, aluminum nitrate, aluminum potassium sulfate, hydrates thereof, and combinations thereof. In certain embodiments, the aluminum-containing polyvalent cation salt is selected from aluminum chloride, aluminum nitrate, aluminum chloride, and combinations thereof.

[0044] The compositions of the present disclosure comprise at least 0.025 wt.%, at least 0.05 wt.%, or at least 0.1 wt.% of a polyvalent cation salt, based on the total weight of the aqueous composition. The compositions of the present disclosure comprise at most 1.75 wt.%, at most 1.5 wt.%, or at most 1.0 wt.% of a polyvalent cation salt, based on the total weight of the aqueous composition.

[0045] Activator - Sodium Fluoride The aqueous oral care fluoride treatment composition of the present disclosure comprises sodium fluoride as an active agent. In certain embodiments, the treatment composition comprises at least 1.0 wt.% based on the total weight of the aqueous composition. In certain embodiments, the treatment composition comprises at most 2.5 wt.% based on the total weight of the aqueous composition.

[0046] During use, the fluoride-releasing composition can be applied to the oral cavity. In one embodiment, the fluoride-releasing composition is typically applied directly to one or more teeth. The fluoride-releasing composition is typically maintained in contact with the teeth for a time sufficient to release a therapeutically effective amount of fluoride. The release rate of fluoride from the fluoride-releasing composition can be measured, for example, by the method described in the Examples section of this disclosure.

[0047] In certain embodiments, the treatment compositions of the present disclosure release at least 30% (or at least 40%, or at least 50%) of the sodium fluoride within 5 minutes. In certain embodiments, the treatment compositions of the present disclosure release at least 50% (or at least 60%, or at least 70%) of the sodium fluoride within 10 minutes. In certain embodiments, the treatment compositions of the present disclosure release at least 80% (or at least 90%, or at least 95%) of the sodium fluoride within 20 minutes.

[0048] In certain embodiments, the treatment compositions of the present disclosure release up to 93% (or up to 90%, or up to 88%) of the sodium fluoride in 1 minute or less. In certain embodiments, the treatment compositions of the present disclosure release up to 97% (or up to 95%, or up to 94%) of the sodium fluoride in 3 minutes or less. In certain embodiments, the treatment compositions of the present disclosure release up to 99% (or up to 98%, or up to 96%) of the sodium fluoride in 5 minutes or less.

[0049] In certain embodiments, the treatment compositions of the present disclosure release 100% (or 98% or more, or 90% or more) of the sodium fluoride within 10 minutes. In certain embodiments, the treatment compositions of the present disclosure release 100% (or 99% or more, or 95% or more) of the sodium fluoride within 15 minutes. In certain embodiments, the treatment compositions of the present disclosure release 100% (or 99% or more, or 98% or more) of the sodium fluoride within 20 minutes.

[0050] Further optional activators The aqueous oral care fluoride treatment compositions of the present disclosure may also contain one or more additional active agents in addition to sodium fluoride, which, if included, typically, but not always, include one or more active agents active in the oral cavity against disorders, diseases, or conditions of the teeth, gums, cheeks, tongue, palate, etc.

[0051] Examples of additional activators that may be used include one or more other fluorine-containing compounds, such as sodium monofluorophosphate, stannous fluoride, calcium fluoride, strontium fluoride, zinc fluoride, potassium zinc fluoride, ammonium fluoride, potassium fluoride, magnesium fluoride, and combinations thereof.

[0052] Examples of additional active agents that can be used include one or more whitening agents, anti-calculus agents, remineralization agents, stannous sources, antibacterial agents, antioxidants, saliva stimulants, breath fresheners, antiplaque agents, anti-inflammatory agents, H2 antagonists, desensitizing agents, nutrients, and proteins.If desired, various combinations of such additional active agents can also be used.When used, one or more additional active agents will typically be used in an amount sufficient to achieve their intended effect.

[0053] When used, the whitening agent may be any suitable whitening agent. Examples of whitening agents include peroxide whitening agents, non-peroxide whitening agents, or both. Peroxide whitening agents include hydrogen peroxide, alkali or alkaline earth metal peroxides, such as sodium peroxide, potassium peroxide, lithium peroxide, magnesium peroxide, calcium peroxide, barium peroxide, glyceryl hydrogen peroxide, alkyl hydrogen peroxide, dialkyl peroxide, peroxy acids or peroxy acid salts, benzoyl peroxide, urea peroxide, and the like. Hydrogen peroxide is the most common. Non-peroxide whitening agents include chlorine dioxide, chlorous acid, and hypochlorous acid. Chlorous acid and hypochlorous acid are typically in the form of alkali or alkaline earth metal salts, such as lithium, potassium, sodium, magnesium, calcium, or barium salts. Colorants, titanium dioxide, and hydroxyapatite may also be used.

[0054] If used, the anticalculus agent can be a variety of suitable anticalculus agents, including, for example, phosphates, polyphosphates, such as pyrophosphates, polyolefin sulfonates, polyolefin phosphates, diphosphonates, phosphonoalkanecarboxylic acids, and salts thereof, typically alkali metal or ammonium salts.

[0055] If used, the remineralizing agent can be a variety of suitable remineralizing agents, including, for example, materials that release calcium ions, phosphorus-containing ions, or both, such as calcium phosphates (e.g., monocalcium phosphate, dicalcium phosphate, and / or tricalcium phosphate), hydroxyapatite, calcium carbonate, and the like.

[0056] Examples of materials that release calcium ions include water-soluble calcium salts, such as calcium chloride, calcium nitrate, calcium gluconate, calcium lactate gluconate, calcium acetate, hydrates thereof, and combinations thereof. In certain embodiments, the calcium salt is selected from calcium chloride, calcium nitrate, hydrates thereof, and combinations thereof.

[0057] Calcium salts may also be used to modify the fluoride release profile.

[0058] When used, the stannous source can be a variety of suitable sources of stannous ions. Stannous ion sources include, for example, stannous halides, organic stannous carboxylates such as stannous formate, stannous acetate, stannous gluconate, stannous lactate, stannous tartrate, and stannous citrate. When the fluoride source is stannous fluoride, it can also function as the stannous source.

[0059] When used, antibacterial agents include a variety of orally acceptable antibacterial agents, such as triclosan, 8-hydroxyquinoline, zinc ions, stannous ions, cupric compounds, phthalic acid and its salts, quaternary ammonium compounds, sanguinarine, salicylanilide, salicylic acid, thymol, eugenol, neomycin, kanamycin, clindamycin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, and chlorhexidine.

[0060] When used, antioxidants can be a variety of orally acceptable antioxidants, examples of which include butylated hydroxyanisone, butylated hydroxytoluene, vitamin A, carotenoids, vitamin E, flavonoids, polyphenols, ascorbic acid or its salts, chlorophyll, melatonin, and the like.

[0061] If used, the saliva stimulant can be a variety of orally acceptable saliva stimulants, examples of which include citric acid, lactic acid, succinic acid, ascorbic acid, adipic acid, fumaric acid, and tartaric acid.

[0062] If used, the breath freshener can be a variety of orally acceptable breath fresheners, examples of which include zinc salts such as zinc gluconate, zinc citrate, and zinc chlorite, alpha-ionone, and the like.

[0063] If used, the antiplaque agent can be a variety of orally acceptable antiplaque agents. Examples include stannous salts, copper, magnesium, or strontium salts, dimethicone copolyols such as cetyl dimethicone copolyol, papain, glucoamylase, glucose oxidase, urea, calcium lactate, calcium glycerophosphate, strontium polyacrylate, and the like. Further examples of antiplaque agents include biofilm inhibitors, particularly those described in U.S. Pat. No. 8,968,709 (Yang et al.).

[0064] When used, anti-inflammatory agents can be a variety of orally acceptable anti-inflammatory agents, including steroids such as flucinolone and hydrocortisone, non-steroidal anti-inflammatory drugs such as ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, ketoprofen, fenoprofen, piroxicam, nabumetone, acetylsalicylic acid, salicylic acid, diflunisal, meclofenamate, mefenamic acid, oxyphenbutazone, phenylbutazone, and the like.

[0065] If used, the H2 antagonist can be a variety of orally acceptable H2 antagonists, examples of which include cimetidine, ethinidine, ranitidine, tiotidine, rupitidine, denetidine, famotidine, roxatidine, pifatidine, ramutidine, zarutidine, nizatidine, mifentidine, lamixotidine, roxitidine, bisfentidine, safotidine, ebrotidine, impromidine, and the like.

[0066] If used, the desensitizing agent can be a variety of orally acceptable desensitizing agents, examples of which include potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate, strontium salts, arginine, acetylsalicylic acid or its salts, salicylic acid or its salts, codeine, acetaminophen, and the like.

[0067] When used, the nutrients can be various orally acceptable nutrients. Examples include vitamins such as vitamin C, vitamin D, thiamine, riboflavin, folic acid, nicotinamide, niacin, pyridoxine, bioflavonoids, etc., supplements such as amino acids, lipoactive agents, fish oil, polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, coenzyme Q10, ubiquinone, minerals such as potassium, etc.

[0068] When used, proteins include a variety of orally acceptable proteins, including milk proteins, peroxide-generating enzymes, amylase, papain, glucoamylase, glucose oxidase, and the like.

[0069] buffer The aqueous oral care fluoride treatment compositions of the present disclosure include a pharmaceutically acceptable buffering agent. The type and amount of such buffering agent are selected to provide a treatment composition having a pH of at least 6, or at least 6.5. In certain embodiments, the type and amount of such buffering agent are selected to provide a treatment composition having a pH of at most 8, at most 7.5, or at most 7. In certain embodiments, the type and amount of such buffering agent are selected to provide a treatment composition having a pH of 6.5-7.5, or at most 7.0. A variety of suitable pharmaceutically acceptable buffering agents can be included. Examples include acetate (e.g., sodium acetate), sodium carbonate, citrate (e.g., sodium citrate), tartrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, tris(hydroxymethyl)-aminomethane, or mixtures thereof.

[0070] thickener In certain embodiments, the aqueous oral care fluoride treatment compositions of the present disclosure include a thickener to provide a composition with a suitable viscosity that allows for the desired application method. For example, a suitable thickener can be used in an amount sufficient to achieve a solution viscosity that is suitable for maintaining the composition in an inverted mouthpiece tray applicator for up to about 4 minutes (a typical time for professionally applied fluoride treatments), yet is fluid enough to have acceptable handling characteristics for a dental technician (e.g., when dispensing into a dental tray applicator). Alternatively, a suitable thickener in an amount sufficient to achieve a solution viscosity suitable for painting onto a tooth surface can be used.

[0071] In certain embodiments, the type and amount of thickening agent is selected to provide the treatment composition with a viscosity of at least 0.5 Pascal-seconds at a shear rate of 1.0 sec / s, hi certain embodiments, the type and amount of thickening agent is selected to provide the treatment composition with a viscosity of at most 500 Pascal-seconds at a shear rate of 1.0 sec / s.

[0072] In certain embodiments, the thickening agent is present in the treatment composition in an amount of less than 2.5% by weight based on the total weight of the aqueous composition, hi certain embodiments, the thickening agent is present in an amount of at least 0.5% by weight based on the total weight of the aqueous composition.

[0073] Suitable thickening agents are typically those that are generally safe for human consumption (FDA approved for internal use), that do not bind fluoride ions, and that do not significantly affect the bioavailability of fluoride ions.

[0074] In certain embodiments, the thickening agent is selected from natural gums, non-acid cellulose derivatives (e.g., hydroxyethyl cellulose), inorganic fillers (e.g., colloidal silica, fumed silica, alumina, titania, and zinc oxide), alkylene oxide polymers (e.g., polyethylene glycol, polypropylene glycol, and copolymers of polyethylene glycol and polypropylene glycol), non-acid modified starches, and combinations thereof.

[0075] Optional Additives In certain embodiments, the aqueous oral care fluoride treatment compositions of the present disclosure include one or more optional additives, including flavoring agents (i.e., flavoring agents) and sweeteners. Various combinations of such additives may be used if desired.

[0076] In certain embodiments, the aqueous oral care fluoride treatment compositions of the present disclosure include a sweetener. A variety of orally acceptable sweeteners can be used. Common sweeteners include xylitol, sorbitol, sucralose, aspartame, saccharin, usually sodium saccharin, and the like. When present, the sweetener can be used in any suitable amount, most often an amount sufficient to impart a pleasant sweetness to the composition. The suitable amount is typically 0.5% to 15% by weight, based on the total weight of the aqueous composition.

[0077] In certain embodiments, the aqueous oral care fluoride treatment composition of the present disclosure includes a flavoring agent. A variety of orally acceptable flavoring agents can be used. Common flavoring agents include peppermint oil, spearmint oil, cherry flavor, citric acid, orange flavor, vanilla, strawberry flavor, coconut flavor, and bubble gum flavor. When present, the flavoring agent can be used in any suitable amount, most often an amount sufficient to impart the desired flavor to the composition. The suitable amount is typically 1% to 4% by weight based on the total weight of the aqueous composition.

[0078] Illustrative Embodiments Embodiment 1 is an aqueous oral care fluoride treatment composition comprising: 0.1% to 3.0% by weight of a crosslinked polyacid having pendant carboxylic acid groups; a pharmaceutically acceptable buffer; 1.0% to 2.5% by weight of sodium fluoride; 0.025% to 1.75% by weight of a polyvalent cation salt; and at least 60% by weight of water, wherein the weight percentages are based on the total weight of the aqueous composition.

[0079] Embodiment 2 is the treatment composition of embodiment 1, wherein the crosslinked polyacid is present in an amount of 0.5% to 1.5% by weight.

[0080] Embodiment 3 is the treatment composition of embodiment 1 or 2, wherein the crosslinked polyacid comprises a homopolymer or copolymer of one or more monomers having one or more carboxylic acid groups.

[0081] Embodiment 4 is the treatment composition of embodiment 3, wherein the crosslinked polyacid comprises a homopolymer or copolymer of acrylic acid, maleic acid, maleic anhydride, itaconic acid, vinyl ethers, alkyl acrylates, sugars, and combinations thereof.

[0082] Embodiment 5 is the treatment composition of embodiment 4, wherein the crosslinked polyacid comprises a homopolymer or copolymer of acrylic acid, maleic acid, itaconic acid, (C10-C30) alkyl acrylate, and combinations thereof.

[0083] Embodiment 6 is a treatment composition according to embodiment 5, wherein the cross-linked polyacid comprises a cross-linked polyacrylic acid homopolymer.

[0084] Embodiment 7 is a treatment composition of any one of embodiments 1-6, wherein the cross-linked polyacid comprises a cross-linker selected from allyl sucrose, allyl pentaerythritol, glycerol, diglycerol, polyglycerol, polyalkenyl alcohol, divinyl glycol, and combinations thereof.

[0085] Embodiment 8 is a treatment composition according to embodiment 7, wherein the polyacrylic acid is cross-linked with allyl sucrose or allyl pentaerythritol.

[0086] Embodiment 9 is a treatment composition according to any one of embodiments 1 to 8, wherein the cross-linked polyacid at 0.5% by weight in a pH 7.5 buffer has a viscosity of 4,000 to 100,000 cP.

[0087] Embodiment 10 is a treatment composition of any one of embodiments 1-9, wherein the multivalent cation salt comprises a +2 multivalent cation, a +3 multivalent cation, or a combination thereof.

[0088] Embodiment 11 is the treatment composition of any one of embodiments 1-10, wherein the multivalent cation salt comprises a multivalent cation selected from Ca, Mg, Ba, Mn, Fe, Zn, Al, Cu, and combinations thereof.

[0089] Embodiment 12 is the treatment composition of embodiment 11, wherein the multivalent cation salt comprises a multivalent cation selected from Ca, Zn, Al, and combinations thereof.

[0090] Embodiment 13 is a treatment composition according to embodiment 12, wherein the multivalent cation salt comprises Al and Ca.

[0091] Embodiment 14 is a treatment composition of any one of embodiments 1-13, wherein the polyvalent cation salt comprises chloride, nitrate, gluconate, lactate, acetate, sulfate, hydrates thereof, and combinations thereof.

[0092] Embodiment 15 is a treatment composition of any one of Embodiments 11-14, wherein the calcium-containing polyvalent cation salt is selected from calcium chloride, calcium nitrate, calcium gluconate, calcium lactate gluconate, calcium acetate, hydrates thereof, and combinations thereof.

[0093] Embodiment 16 is a treatment composition according to embodiment 15, wherein the calcium-containing polyvalent cation salt is selected from calcium chloride, calcium nitrate, hydrates thereof, and combinations thereof.

[0094] Embodiment 16 is a treatment composition of any one of Embodiments 11-16, wherein the aluminum-containing polyvalent cation salt is selected from aluminum chloride, aluminum sulfate, aluminum nitrate, aluminum potassium sulfate, hydrates thereof, and combinations thereof.

[0095] Embodiment 17 is the treatment composition of any one of embodiments 1-16, wherein the multivalent cation salt is present in a total amount of 0.05% to 1.5% by weight, or 0.1% to 1.0% by weight.

[0096] Embodiment 18 is a treatment composition according to any one of embodiments 1 to 17, further comprising a thickening agent.

[0097] Embodiment 19 is a treatment composition according to embodiment 18, wherein the thickening agent is present in an amount sufficient to provide the composition with a viscosity of 0.5 to 500 Pascal-seconds at a shear rate of 1.0 Pa / sec.

[0098] Embodiment 20 is a treatment composition according to embodiment 18 or 19, wherein the thickening agent is present in an amount of at least 0.5% and less than 2.5% by weight.

[0099] Embodiment 21 is a treatment composition according to any one of embodiments 18-20, wherein the thickening agent is selected from natural gums, non-acid cellulose derivatives, inorganic fillers, alkylene oxide polymers, non-acid modified starches, and combinations thereof.

[0100] Embodiment 22 is a treatment composition according to any one of embodiments 1 to 21, having a pH of 6 to 8, or a pH of 6.5 to 7.5.

[0101] Embodiment 23 is a treatment composition according to embodiment 22, having a pH of 6-7, or a pH of 7.0.

[0102] Embodiment 24 is a treatment composition according to any one of embodiments 1 to 23, comprising less than 5% by weight of an organic solvent acting as a carrier liquid (e.g., ethanol).

[0103] Embodiment 25 is a treatment composition according to any one of embodiments 1 to 24, which releases at least 30% (or at least 40%, or at least 50%) of the sodium fluoride in 5 minutes or less.

[0104] Embodiment 26 is a treatment composition according to any one of embodiments 1 to 25, which releases at least 50% (or at least 60%, or at least 70%) of the sodium fluoride in 10 minutes or less.

[0105] Embodiment 27 is a treatment composition according to any one of embodiments 1 to 26, which releases at least 80% (or at least 90%, or at least 95%) of the sodium fluoride in 20 minutes or less.

[0106] Embodiment 28 is a treatment composition according to any one of embodiments 1 to 27, which releases up to 93% (or up to 90%, or up to 88%) of the sodium fluoride in 1 minute or less.

[0107] Embodiment 29 is a treatment composition according to any one of embodiments 1 to 28, which releases up to 97% (or up to 95%, or up to 94%) of the sodium fluoride in 3 minutes or less.

[0108] Embodiment 30 is a treatment composition according to any one of embodiments 1 to 29, which releases up to 99% (or up to 98%, or up to 96%) of the sodium fluoride in 5 minutes or less.

[0109] Embodiment 31 is a treatment composition according to any one of embodiments 1 to 30, which releases 100% (or 98% or more, or 90% or more) of the sodium fluoride in 10 minutes or less.

[0110] Embodiment 32 is a treatment composition according to any one of embodiments 1-31, which releases 100% (or 99% or more, or 95% or more) of the sodium fluoride in 15 minutes or less.

[0111] Embodiment 33 is a treatment composition according to any one of embodiments 1 to 32, which releases 100% (or 99% or more, or 98% or more) of the sodium fluoride in 20 minutes or less.

[0112] Embodiment 34 is a treatment composition according to any one of embodiments 1 to 33, comprising at least 70% (or at least 80%) water by weight.

[0113] Embodiment 35 is a treatment composition according to any one of embodiments 1 to 34, comprising up to 96% (or up to 90%) water by weight.

[0114] Embodiment 36 is a treatment composition according to any one of embodiments 1 to 35, comprising one or more active agents in addition to sodium fluoride.

[0115] Embodiment 37 is a treatment composition according to embodiment 36, wherein the one or more active agents comprise a whitening agent, anticalculus agent, remineralization agent, stannous source, antibacterial agent, antioxidant, saliva stimulant, breath freshener, antiplaque agent, anti-inflammatory agent, H2 antagonist, desensitizing agent, nutrient, protein, or combinations thereof.

[0116] Embodiment 38 is a treatment composition according to any one of embodiments 1 to 37, further comprising a flavoring agent.

[0117] Embodiment 39 is a treatment composition according to any one of embodiments 1 to 38, further comprising a sweetener.

[0118] Embodiment 40 is a method of providing fluoride to a patient's dental surfaces, comprising applying to the patient's dental surfaces an aqueous oral care fluoride treatment composition of any one of embodiments 1-39.

[0119] Embodiment 41 is the method of embodiment 40, wherein applying comprises painting the treatment composition onto the patient's tooth surface.

[0120] Embodiment 42 is the method of embodiment 40, wherein applying comprises dispensing the treatment composition into a dental tray and attaching the tray with the treatment composition therein to the patient's tooth surfaces.

[0121] Embodiment 43 is the method of embodiment 42, wherein the dental tray comprises an orthodontic aligner treatment tray.

[0122] Embodiment 44 is a method of reducing the incidence of dental caries in a patient in need thereof, comprising applying to the patient's dental surfaces an aqueous oral care fluoride treatment composition of any one of embodiments 1-39.

[0123] Embodiment 45 is the method of embodiment 44, wherein applying comprises painting the treatment composition onto the patient's tooth surface.

[0124] Embodiment 46 is the method of embodiment 44, wherein applying comprises dispensing the treatment composition into a dental tray and attaching the tray with the treatment composition therein to the patient's tooth surfaces.

[0125] Embodiment 47 is the method of embodiment 46, wherein the dental tray comprises an orthodontic aligner treatment tray. [Example]

[0126] The objects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention. These examples are merely for illustrative purposes and are not meant to limit the scope of the appended claims.

[0127] Example [Table 1]

[0128] pH test pH testing was performed with a standard pH meter after calibration. The pH meter was an ACCUMET model 15 pH meter manufactured by Fisher Scientific. Measurements were performed by inserting the pH probe into the solution, waiting 2 minutes, and recording the pH value. The pH values ​​are listed in the tables in the examples.

[0129] Fluoride Release Rate Test Fluoride release rates were measured using a Mettler Toledo T70 titrator. A Cole Parmer fluoride electrode was first calibrated in parts per million (ppm) of fluoride using TISAB III prior to measuring samples each day for fluoride release (a concentrated solution of Total Ionic Strength Adjustment Buffer (TISAB III) is used with a fluoride ion-selective electrode, Sigma Aldrich). Each example composition was applied to a RINZL Plastic microscope slide, measuring 2.54 cm on each side of the slide. 2 The sample was coated with a thin layer. The total weight of the coating was approximately 0.045 g. The fluoride meter titration cup was filled with 50 mL of a mixture of 45 mL of MilliQ DI water and 5 mL of TISAB III concentrate. A fluoride ion-selective electrode was placed in the titration cup of the diluted TISAB III solution, and the meter was allowed to equilibrate for 30 seconds before analyzing each sample. After 30 seconds, the clamped sample was reduced to 50 mL of diluted TISAB III solution. Fluoride release (mV) was measured at various time points during a 30-minute titration in a Mettler Toledo T70 titrator. Fluoride release rates were calculated against a fluoride standard calibration curve. The average of two titrations was reported for each example.

[0130] Preparation of buffered CARBOPOL polyacid solution: Alkaline chemicals such as disodium hydrogen phosphate and triethanolamine were first dissolved in deionized (DI) water in a glass bottle to form a clear solution. CARBOPOL 974P NF was then added to the glass bottle, which was roller mixed to form a slightly viscous, slightly cloudy solution. The pH was measured with a standard pH meter. Four different buffered CARBOPOL solutions (BCS) were prepared with the following formulations, shown in Table 2.

[0131] [Table 2]

[0132] Preparation Procedures of the Examples The appropriate amount of buffered CARBOPOL polyacid solution was added to a plastic bottle, and then the calculated amounts of sodium fluoride, xylitol, and flavor / sweetener were added to the plastic bottle with magnetic stirring for 30 minutes to dissolve all of these chemicals into the aqueous example solution. The polyvalent cation salts were first dissolved in DI water in a separate glass bottle, and then these salt solutions were slowly added to the CARBOPOL solution in the plastic bottle. The mixture was mixed with magnetic stirring for 1 hour. Hydroxyethyl cellulose (HEC) was then added to the example solution, which was mixed with magnetic stirring for an additional 30 minutes. Finally, the example composition was further mixed on a roller mixer for 1-2 days to form a viscous aqueous coating solution. The total amounts for each example, in grams, are listed in Tables 3A-3E.

[0133] [Table 3]

[0134] [Table 4]

[0135] [Table 5]

[0136] [Table 6]

[0137] [Table 7]

[0138] [Table 8]

[0139] [Table 9]

[0140] [Table 10]

[0141] [Table 11]

[0142] The entire disclosures of the patents, patent documents, and publications cited herein are incorporated by reference in their entirety, as if each were individually incorporated. Various modifications and alterations to the present disclosure will become apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. It is understood that the present disclosure is not intended to be unduly limited by the exemplary embodiments and examples set forth herein, and that such examples and embodiments are presented merely as examples within the scope of the present disclosure, which is intended to be limited only by the claims set forth herein as follows.

Claims

1. 1. A colloidal dispersion composition for use in oral care, comprising: 1.0% to 2.5% by weight of a fluoride-releasing composition effective to release fluoride to the tooth surface; 0.1% to 3.0% by weight of a crosslinked polyacid polymer; 0.025% to 1.75% by weight of a water-soluble polyvalent cation salt; a thickening agent selected from non-acid cellulose derivatives, inorganic fillers, alkylene oxide polymers, non-acid modified starches, and combinations thereof; a pharmaceutically acceptable buffer; and water present in an amount of at least 60% by weight based on the total weight of said colloidal dispersion composition; and characterized by a viscosity of 0.5 to 500 Pascal-seconds at a shear rate of 1.0 sec-1; the fluoride-releasing composition comprises sodium fluoride; A colloidal dispersion composition wherein the crosslinked polyacid polymer has one or more carboxylic acid groups.

2. 10. The colloidal dispersion composition of claim 1, wherein the fluoride-releasing composition comprises sodium monofluorophosphate, stannous fluoride, calcium fluoride, strontium fluoride, zinc fluoride, potassium zinc fluoride, ammonium fluoride, potassium fluoride, magnesium fluoride, or a combination thereof.

3. 3. The colloidal dispersion composition of claim 2, wherein the sodium monofluorophosphate, stannous fluoride, calcium fluoride, strontium fluoride, zinc fluoride, potassium zinc fluoride, ammonium fluoride, potassium fluoride, magnesium fluoride, or combinations thereof are present in an amount of at least 1.0 wt %, based on the total weight of the colloidal dispersion composition.

4. The crosslinked polyacid polymer may be prepared by mixing the following monomers: acrylic acid, maleic acid, maleic anhydride, itaconic acid, vinyl ether, C １０－３０ 10. The colloidal dispersion composition of claim 1, derived from one or more of an alkyl acrylate and a sugar.

5. 10. The colloidal dispersion composition of claim 1, wherein the crosslinked polyacid polymer comprises a polyacid polymer crosslinked with a polyalkenyl alcohol or divinyl glycol.

6. 10. The colloidal dispersion composition of claim 1, wherein the crosslinked polyacid polymer comprises a polyacid polymer crosslinked with allyl sucrose, allyl pentaerythritol, glycerol, diglycerol, polyglycerol, polyalkenyl alcohol, divinyl glycol, or combinations thereof.

7. 10. The colloidal dispersion composition of claim 1, wherein the crosslinked polyacid polymer comprises polyacrylic acid crosslinked with allylpentaerythritol.

8. 10. The colloidal dispersion composition of claim 1, wherein the multivalent cation salt comprises calcium, magnesium, barium, manganese, iron, zinc, aluminum, copper, or a combination thereof.

9. 10. The colloidal dispersion composition of claim 1, wherein the polyvalent cation salt is selected from calcium chloride, calcium nitrate, calcium gluconate, calcium lactate gluconate, calcium acetate, hydrates thereof, and combinations thereof.

10. 2. The colloidal dispersion composition of claim 1, wherein the polyvalent cation salt is selected from aluminum chloride, aluminum sulfate, aluminum nitrate, aluminum potassium sulfate, hydrates thereof, and combinations thereof.

11. 10. The colloidal dispersion composition of claim 1, wherein said thickening agent is a non-acid cellulose derivative.

12. 12. The colloidal dispersion composition of claim 11, wherein the pharmaceutically acceptable buffering agent is selected from sodium acetate, sodium carbonate, sodium citrate, disodium hydrogen phosphate, triethanolamine, or combinations thereof.

13. 10. The colloidal dispersion composition of claim 1, characterized by a pH of 6 to 8.

14. 10. The colloidal dispersion composition of claim 1, further comprising one or more remineralizing agents.

15. 10. The colloidal dispersion composition of claim 1 for use in a method of treating a tooth surface with fluoride, said method comprising: contacting the colloidal dispersion composition with a tooth surface; and maintaining the colloidal dispersion composition in contact with the tooth surface for a time effective to release fluoride from the colloidal dispersion composition to the tooth surface.

16. 16. The colloidal dispersion composition of claim 15, wherein said contacting comprises placing a dental tray on the tooth surface, and said colloidal dispersion composition is dispensed into said dental tray.

17. 16. The colloidal dispersion composition of claim 15, wherein the colloidal dispersion composition releases fluoride at a rate of up to 93% of the fluoride it contains in one minute.

18. Treating the tooth surface with fluoride comprises: Reduce the incidence of dental caries, Remineralize tooth surfaces 16. The colloidal dispersion composition of claim 15, which provides one or more of the following:

19. 10. The colloidal dispersion composition of claim 1, wherein fluoride is released from said colloidal dispersion composition at a rate that releases up to 93% of the contained fluoride in one minute as measured according to the Fluoride Release Rate Test.

Images